Business
EKO International Corp – Summary of NeuroVasc Clinical Inc.’s (NVCI) Business
EKO International Corp – Summary of NeuroVasc Clinical Inc.’s (NVCI) Business.
About this update from Eko International Corporation
[{"type":"text","content":" EKO International Corp – Summary of NeuroVascClinical Inc.’s (NVCI) Business Burlington, Ontario One of thegreatest challenge facing North American health care today is diabetes. It isestimated that there are 60 million diabetics in North American in 2012 andthat number is climbing rapidly. Approximately 65% of diabetics will developperipheral neuropathy, a painful and often irreversible condition affectingboth lower limbs. It begins as tingling and mild pain in the feet andeventually it becomes painless as the nerve function is compromised andsensation is lost. The loss of nerve function and decreased vascularity in the lowerlimb makes the patient susceptible to ulcers and wounds on the foot that willheal very slowly if at all. This opens up the risk for infection and greatlyincreases the likelihood of amputation. The cost in human terms and infinancial terms to the health care system is staggering. It is estimated thereis an amputation every 30 seconds in North America. NeuroVascClinical Inc. has brought a solution to the North American market place. Thepatented technology called FREMS is an FDA and Health Canada approved devicethat uses a patented electrical frequency and duty cycle to stimulate bloodvessel re-growth and tissue regeneration in tissue that has compromised nerveand blood vessel function. The patient is treated 10 times once daily for 40minutes and the effects on the tissue will last up to 18 month depending on theoverall health of the patient. Thus this treatment becomes part of themaintenance of the lower limb for the diabetic patient as they age and will bea key player in the prevention of painful neuropathy and the development ofdangerous wounds. Each FREMS devicecan treat approx. 8-10 patients a day.The sale of eachFREMS device will generate approx. $ 8,000 of gross profit for EKOConsumablesupplies for each treatment will generate approx. $3.00 of gross profit forEKO NeuroVascClinical will be partnering with leading doctors and clinics in North Americato provide this service locally. Training and patient education will beprovided centrally by NeuroVasc Clinical and treatment will be provided atclinics certified by NeuroVasc Clinical locally. Each FREMS deviceis expected to generate betw...